DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Capricor Therapeutics Q4 EPS $(0.34), Inline, Sales $222.1K Down From $648.082K YoY

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate. This is a 209.09 percent decrease over losses of $(0.11) per share from the same period last

Benzinga · 03/18/2020 20:02

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate. This is a 209.09 percent decrease over losses of $(0.11) per share from the same period last year. The company reported $222.1 thousand in sales this quarter. This is a 65.73 percent decrease over sales of $648.082 thousand the same period last year.